Excel Industries Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/oixm315fw7m8y4qmuz0tktlz.pdf

Key Takeaways


Agrochemical Demand Disruption

Ravi Shroff: "We see normalization of demand to some extent due to abundant groundwater levels resulting in a better winter crop cycle. This is our expectation if there are no other disruptions and full-scale revival of demand could happen sometime in Q4 or little beyond that."

Diversification: Contract Manufacturing & Performance Solutions

Ravi Shroff: "This arrangement will leverage the customer's market access for the downstream end products and our strengths in core areas to deliver a win-win for both organizations. For our company, this is a significant step towards strengthening our position in contract manufacturing and will reduce our dependence on the agrochemical sector."

Margins: Compressed Today, Guided to Recover


CAPEX & Capacity


R&D Build-Out

Ravi Shroff: "We are actively exploring what other strengths are required. And along with the new R&D center whatever we require in terms of other infrastructure, people as well, we have evaluated all of that to make sure that R&D becomes a core pillar of growth."

Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA margin13% to 15% for full year FY26 and on an ongoing basisFY26
Demand normalizationFull-scale agrochemical demand revival, conditional on inventory clearance pace and no further disruptionsQ4 FY26 or beyond
New contract manufacturing lineDedicated production line commissioned; ₹40 crores investment; ₹35-40 crores annual revenue ex-raw materialCommission by June 2026; revenue staggered over 12-18 months thereafter
Biocide plant revenue₹15 crores full-year revenue from newly commissioned capacityFY26
Polymer contract revenue₹10-12 crores topline at full streamAt full stream (timing unspecified)
CAPEX₹200-300 crores total, including maintenance and growthOver next three years
New R&D centerFacility to become operationalQ3 FY26

Key Metrics

MetricQ2 FY26
Revenue₹270 cr, down from ₹310 cr in Q1 FY26
Exports share17.7% of total revenue
EBITDA₹30 cr, down 29% sequentially from ₹42 cr
Profit after tax₹19 cr, down from ₹34 cr in Q1 FY26
H1 FY26 revenue₹580 cr, up 9% YoY from ₹534 cr
H1 FY26 EBITDA₹72 cr, down from ₹88 cr in H1 FY25
H1 FY26 profit after tax₹52 cr, down 20% YoY
Full-year EBITDA margin guidance13% to 15%, maintained
Capacity utilization70% to 75% across the company
Inventory increase15% to 20% from Q1 FY26, agrochemical segment
New contract manufacturing investment₹40 cr, dedicated production line, commissioning by June 2026
New contract manufacturing expected annual revenue₹35 cr to ₹40 cr, excluding raw material cost, EBITDA accretive
New biocide plant investment₹10.33 cr, commissioned October 2025
New biocide plant expected full-year revenue₹15 cr, EBITDA accretive
Three-year CAPEX plan₹200 cr to ₹300 cr, including maintenance and growth CAPEX